Bausch + Lomb was valued at $6.48 billion in the company’s U.S. market debut on May 6 as the eye-care company’s shares opened nearly 3 percent above an offer price that was well below the targeted range.
Experimental contact lenses that not only improve vision, but also ward off itchiness due to allergies, got a boost with the completion of two late-stage studies, according to a new report.
